Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: Three-center study

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 951-958

  Bortlik, Martin ^a   Machkova, Nadezda ^a   Duricova, Dana ^a   Malickova, Karin ^b   Hrdlicka, Ludek ^a   Lukas, Martin ^a   Kohout, Pavel ^c   Shonova, Olga ^d   Lukas, Milan ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d Hospital Ceske Budejovice   (Czech Republic)

Author keywords

Adalimumab; Inflammatory bowel disease; Infliximab; Outcome; Pregnancy

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CROHN DISEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HIP DYSPLASIA; HUMAN; LIVE BIRTH; MOTHER; NEWBORN ASSESSMENT; NEWBORN DISEASE; OUTCOME ASSESSMENT; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RELAPSE; REMISSION; THERAPEUTIC ABORTION; ULCERATIVE COLITIS; UMBILICAL CORD BLOOD;

ABORTION, SPONTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIRTH WEIGHT; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; PRENATAL CARE; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84880404539     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.812141     Document Type: Article

References (17)

1. Zelinkova Z, Mensink PB, Dees J, Kuipers EJ, van der Woude CJ. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010;45:46-50.
2. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92.
3. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
4. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
5. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011;106:214-23.
6. van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010;4:493-510.
7. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4:63-101.
8. Mahadevan U, Martin CF, Sandler RS, Kane S, Dubinsky M, Lewis JD, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012;142:S-149.
9. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.
10. Zelinkova Z, van der Ent C, Bruin K, van Baalen O, Vermeulen HG, Smalbraak H, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11:318-21.
11. Casanova MJ, Chaparro M, Domenech E, Barreiro-de AM, Bermejo F, Iglesias E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40.
12. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830-7.
13. Seirafi M, De Vroey B, Cosnes J, Treton XR, Allez M, Marteau P, et al. Anti-TNF therapy and pregnancy in inflammatory bowel disease: a prospective cohort study from the GETAID. Gut 2011;60:A34.
14. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
15. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63.
16. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT registry. Am J Gastroenterol 2012;107: 1409-22.
17. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.